A Study of DTC in Patients With AIDS and AIDS Related Complex

N/ACompletedNCT00002069

Merieux Institute

Overview

To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

HIV Infections

Interventions

Ditiocarb sodiumDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria Concurrent Medication: Allowed: * Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * Active opportunistic infection or progressive Kaposi's sarcoma (KS). * Dementia. * Lymphoma. Concurrent Medication: Excluded within 3 weeks of study entry: * Other experimental AIDS therapy. Patients with the following are excluded: * Active opportunistic infection or progressive Kaposi's sarcoma (KS). Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.

Locations (8)

Univ of Arizona / Arizona Cancer Ctr

Tucson, Arizona, United States

USC School of Medicine / Norris Cancer Hosp

Los Angeles, California, United States

San Francisco AIDS Clinic / San Francisco Gen Hosp

San Francisco, California, United States

Portion Med Group

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.